{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:32:16Z","timestamp":1793655136191,"version":"4.5.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004320","name":"Philips","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.ajog.2021.05.007","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:02:53Z","timestamp":1621382573000},"page":"407.e1-407.e16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer"],"prefix":"10.1016","volume":"225","author":[{"given":"Willem Jan","family":"van Weelden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy I.","family":"Lalisang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Bulten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Lindemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heleen J.","family":"van Beekhuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Trum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorry","family":"Boll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrica M.J.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc R.C.W.","family":"van Lonkhuijzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Refika","family":"Yigit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Forsse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petronella O.","family":"Witteveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadra","family":"Galaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"van Ginkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Bignotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vit","family":"Weinberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne","family":"Sweegers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith R.","family":"Kroep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Cabrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc P.L.M.","family":"Snijders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rcia A.","family":"Inda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ane Gerda Z.","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Krakstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"van de Stolpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna M.A.","family":"Pijnenborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2021.05.007_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ajog.2021.05.007_bib2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/jnci\/djx214","article-title":"International patterns and trends in endometrial cancer incidence, 1978-2013","volume":"110","author":"Lortet-Tieulent","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"Suppl2","key":"10.1016\/j.ajog.2021.05.007_bib3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ijgo.12612","article-title":"Cancer of the corpus uteri","volume":"143","author":"Amant","year":"2018","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.ajog.2021.05.007_bib4","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1016\/j.ejca.2013.06.016","article-title":"Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial","volume":"49","author":"Trovik","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ajog.2021.05.007_bib5","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/bjc.2016.235","article-title":"L1CAM expression in endometrial carcinomas: an ENITEC collaboration study","volume":"115","author":"van der Putten","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajog.2021.05.007_bib6","doi-asserted-by":"crossref","first-page":"e631","DOI":"10.1016\/j.ijrobp.2011.04.013","article-title":"Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma","volume":"81","author":"Creutzberg","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ajog.2021.05.007_bib7","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.2001.19.20.4048","article-title":"Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study","volume":"19","author":"Hoskins","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2021.05.007_bib8","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer","volume":"380","author":"Matei","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2021.05.007_bib9","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology\/GOG0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2021.05.007_bib10","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1200\/JCO.1999.17.6.1736","article-title":"Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group","volume":"17","author":"Thigpen","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2021.05.007_bib11","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1200\/JCO.1996.14.2.357","article-title":"High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study","volume":"14","author":"Lentz","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2021.05.007_bib12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ygyno.2003.09.018","article-title":"Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"92","author":"Whitney","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2021.05.007_bib13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1471-2407-14-68","article-title":"Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)","volume":"14","author":"Lindemann","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ajog.2021.05.007_bib14","first-page":"429","article-title":"Past, present, and future of hormonal therapy in recurrent endometrial cancer","volume":"6","author":"Carlson","year":"2014","journal-title":"Int J Womens Health"},{"key":"10.1016\/j.ajog.2021.05.007_bib15","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ygyno.2016.08.333","article-title":"Working together to shape the endometrial cancer research agenda: the top ten unanswered research questions","volume":"143","author":"Wan","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2021.05.007_bib16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ygyno.2018.12.018","article-title":"Endocrine therapy in endometrial cancer: an old dog with new tricks","volume":"153","author":"Jerzak","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2021.05.007_bib17","first-page":"1","article-title":"Therapeutic targets and opportunities in endometrial cancer: update on endocrine therapy and nonimmunotherapy targeted options","volume":"40","author":"MacKay","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ajog.2021.05.007_bib18","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1136\/ijgc-2020-001309","article-title":"Improving response to progestin treatment of low-grade endometrial cancer","volume":"30","author":"Baxter","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ajog.2021.05.007_bib19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.humpath.2020.12.003","article-title":"The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: a European Network for Individualized Treatment of Endometrial Cancer Collaboration Study","volume":"109","author":"van Weelden","year":"2021","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ajog.2021.05.007_bib20","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ygyno.2008.10.032","article-title":"Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer","volume":"112","author":"Jongen","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2021.05.007_bib21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ygyno.2007.03.042","article-title":"Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study","volume":"106","author":"Singh","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2021.05.007_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0134969","article-title":"Endometrial endometrioid carcinoma metastases show decreased ER-alpha and PR-A expression compared to matched primary tumors","volume":"10","author":"Bartosch","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ajog.2021.05.007_bib23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/PAI.0000000000000402","article-title":"Immunohistochemical profiles of endometrioid endometrial carcinomas with and without metastatic disease","volume":"26","author":"Geels","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.ajog.2021.05.007_bib24","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1016\/j.ejca.2014.09.003","article-title":"Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions","volume":"50","author":"Tangen","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ajog.2021.05.007_bib25","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1535-7163.MCT-19-0318","article-title":"Estrogen receptor pathway activity score to predict clinical response or resistance to neoadjuvant endocrine therapy in primary breast cancer","volume":"19","author":"Inda","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ajog.2021.05.007_bib26","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3390\/cancers12040802","article-title":"ER and PI3K pathway activity in primary ER positive breast cancer is associated with progression-free survival of metastatic patients under first-line tamoxifen","volume":"12","author":"Sieuwerts","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ajog.2021.05.007_bib27","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41416-020-0925-4","article-title":"Oestrogen receptor pathway activity is associated with outcome in endometrial cancer","volume":"123","author":"van Weelden","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajog.2021.05.007_bib28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ajog.2021.05.007_bib29","first-page":"19","article-title":"Pathology databanking and biobanking in the Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive","volume":"29","author":"Casparie","year":"2007","journal-title":"Cell Oncol"},{"key":"10.1016\/j.ajog.2021.05.007_bib30","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1158\/0008-5472.CAN-13-2515","article-title":"Selection of personalized patient therapy through the use of knowledge-based computational models that identify tumor-driving signal transduction pathways","volume":"74","author":"Verhaegh","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.ajog.2021.05.007_bib31","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ygyno.2017.07.002","article-title":"Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis","volume":"147","author":"Ethier","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2021.05.007_bib32","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1158\/1078-0432.CCR-19-0471","article-title":"Everolimus, letrozole, and metformin in women with advanced or recurrent endometrioid endometrial cancer: a multi-center, single arm, Phase II study","volume":"26","author":"Soliman","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajog.2021.05.007_bib33","doi-asserted-by":"crossref","first-page":"370.e1","DOI":"10.1016\/j.ajog.2020.10.003","article-title":"Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer","volume":"224","author":"Chung","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.05.007_bib34","unstructured":"Fritz MA, Speroff L. Clinical gynecologic endocrinology and infertility. Philadelphia, PA: Lippincott Williams & Wilkins; 2011."},{"key":"10.1016\/j.ajog.2021.05.007_bib35","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nature14583","article-title":"Progesterone receptor modulates ERalpha action in breast cancer","volume":"523","author":"Mohammed","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ajog.2021.05.007_bib36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ygyno.2019.05.007","article-title":"Phase 2 study of anastrozole in recurrent estrogen (ER)\/progesterone (PR) positive endometrial cancer: the Paragon trial - ANZGOG 0903","volume":"154","author":"Mileshkin","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2021.05.007_bib37","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1200\/JCO.2001.19.2.364","article-title":"Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study","volume":"19","author":"Thigpen","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2021.05.007_bib38","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1002\/cncr.25515","article-title":"A\u00a0phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma","volume":"116","author":"Slomovitz","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ajog.2021.05.007_bib39","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ygyno.2010.10.015","article-title":"Phase II study of fulvestrant in recurrent\/metastatic endometrial carcinoma: a Gynecologic Oncology Group Study","volume":"120","author":"Covens","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2021.05.007_bib40","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ajog.2021.05.007_bib41","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/annonc\/mdy545","article-title":"Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial","volume":"30","author":"Herbst","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ajog.2021.05.007_bib42","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41416-020-0925-4","article-title":"Oestrogen receptor pathway activity is associated with outcome in endometrial cancer","volume":"123","author":"van Weelden","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ajog.2021.05.007_bib43","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1535-7163.MCT-19-0318","article-title":"Estrogen receptor pathway activity score to predict clinical response or resistance to neoadjuvant endocrine therapy in primary breast cancer","volume":"19","author":"Inda","year":"2020","journal-title":"Mol Cancer Ther"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937821005548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937821005548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:34:18Z","timestamp":1757590458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937821005548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0002937821005548"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2021.05.007","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2021.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}